XML 61 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Contractual Clinical Trials (Details)
 12 Months Ended
Dec. 31, 2023
USD ($)
Integer
Other Commitments [Line Items]  
Remaining financial contractual commitment | $ $ 6,013,000
Phase 1b [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with carboplatin, etoposide and atezolizumab in small cell lung cancer
Estimated Start Date March 2021
Estimated End Date March 2026
Remaining financial contractual commitment | $ $ 2,433,000
Phase 1b [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 14
Phase 1b [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 36
Phase 1b Two [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with doxorubicin in sarcoma
Estimated Start Date June 2023
Estimated End Date June 2024
Remaining financial contractual commitment | $ $ 3,580,000
Phase 1b Two [Member] | Minimum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 9
Phase 1b Two [Member] | Maximum [Member]  
Other Commitments [Line Items]  
Number of Patients in Trial 18
Phase 0 Pharmacology Study [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 in high grade gliomas [1]
Estimated Start Date January 2019 [1]
Estimated End Date August 2022 [1]
Number of Patients in Trial 7 [1]
Randomized Phase 2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description Doxorubicin with or without LB-100 in sarcoma [2]
Estimated Start Date July 2024 [2]
Estimated End Date June 2026 [2]
Number of Patients in Trial 150 [2]
Phase 1b/2 [Member]  
Other Commitments [Line Items]  
Clinical trial, description LB-100 combined with dostarlimab in ovarian clear cell carcinoma [1]
Estimated Start Date March 2024 [1]
Estimated End Date December 2025 [1]
Number of Patients in Trial 21 [1]
[1] There is no remaining financial contractual commitment associated with this clinical trial.
[2] The financial contractual commitment of the GEIS Randomized Phase 2 clinical trial is included in the financial contractual commitment of the GEIS Phase 1b trial. .